Untitled

Warrenfeltz, Susanne; Pavlik, Stephen; Datta, Susmita; Kraemer, Eileen; Benigno, Benedict B.; McDonald, John F.

doi:10.1186/1476-4598-3-27

Cited by 40 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding of similar gene expression profiles in LMP and invasive tumors was unexpected as it is widely accepted that these tumors arise via distinct pathways [20,21]. Our results are in agreement, however, with previous findings in serous ovarian tumors [22,23] but contrast with other studies [21,24-26].…”

Section: Discussionsupporting

confidence: 89%

“…Our results are in agreement, however, with previous findings in serous ovarian tumors [22,23] but contrast with other studies [21,24-26]. In support of the current findings of similar gene expression profiles in LMP and invasive tumors, minimal differences in gene expression profiles have been reported previously in studies that compared well-differentiated with poorly-differentiated serous invasive tumors [6,26].…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer

et al. 2009

View full text Add to dashboard Cite

BackgroundThe malignant potential of serous ovarian tumors, the most common ovarian tumor subtype, varies from benign to low malignant potential (LMP) tumors to frankly invasive cancers. Given the uncertainty about the relationship between these different forms, we compared their patterns of gene expression.MethodsExpression profiling was carried out on samples of 7 benign, 7 LMP and 28 invasive (moderate and poorly differentiated) serous tumors and four whole normal ovaries using oligonucleotide microarrays representing over 21,000 genes.ResultsWe identified 311 transcripts that distinguished invasive from benign tumors, and 20 transcripts that were significantly differentially expressed between invasive and LMP tumors at p < 0.01 (with multiple testing correction). Five genes that were differentially expressed between invasive and either benign or normal tissues were validated by real time PCR in an independent panel of 46 serous tumors (4 benign, 7 LMP, 35 invasive). Overexpression of SLPI and WNT7A and down-regulation of C6orf31, PDGFRA and GLTSCR2 were measured in invasive and LMP compared with benign and normal tissues. Over-expression of WNT7A in an ovarian cancer cell line led to increased migration and invasive capacity.ConclusionThese results highlight several genes that may play an important role across the spectrum of serous ovarian tumorigenesis.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 88%

Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Global approaches have also been applied for ovarian cancer prognosis evaluation, in particular using a cDNA microarray [9][10][11][12], and for tumour classification using 2-DE [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1‐R10

Moguen¹,

Lincet²,

Deslandes³

et al. 2006

Proteomics

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of mortality due to gynaecological cancer. Despite a good response to surgery and initial chemotherapy essentially based on cisplatin (cis-diamino-dichloro-platinum(II) (CDDP)) compounds, late tumour detection and frequent recurrences with chemoresistance acquisition are responsible for poor prognosis. Several mechanisms have been implicated in CDDP resistance but they are not sufficient to exhaustively explain this resistance emergence. We applied a proteomic approach based on 2-DE coupled with MS to identify proteins associated with the chemoresistance process. We first established a proteomic pattern of the CDDP sensitive ovarian cell line IGROV1 using MALDI-TOF-MS and PMF. We then compared this 2-D pattern with that of the CDDP-resistant counterpart IGROV1-R10. Among the 40 proteins identified, cytokeratins 8 and 18 and aldehyde dehydrogenase 1 were overexpressed in IGROV1-R10, whereas annexin IV was down-regulated. These observations have been confirmed by Western blotting. The characterization of such variations could lead to the development of new protein markers or to the establishment of new therapeutic strategies. Moreover, the identification of proteins involved in CDDP resistance in ovarian tumours would be useful in completing our understanding on this complex mechanism.

show abstract

“…Unlike traditional PCR, this method employs fluorescent dyes to allow an instrument to detect RNA levels during the PCR process. This allows scientists to measure expression levels in the diseased state to diagnose patient samples with precision in relatively short periods of time [26-28]. …”

Section: Emerging Technology For Precise Diagnosis Of Ovarian Cancermentioning

confidence: 99%

Precision targeted therapy of ovarian cancer

Sapiezynski

Taratula

Rodrı́guez-Rodrı́guez

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

Untitled

Cited by 40 publications

References 47 publications

Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer

Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer

Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1‐R10

Precision targeted therapy of ovarian cancer

Contact Info

Product

Resources

About